Beyond the Scales: How Wegovy Is Now Saving Hearts — and What It Means for You

For most people, Wegovy has been synonymous with one thing: weight loss. The weekly injection, containing semaglutide, became one of the most talked-about medicines in the UK almost overnight — celebrated for its remarkable results in helping people living with obesity shed significant weight. But in April 2026, something important shifted. New guidance from the National Institute for Health and Care Excellence (NICE) officially repositioned Wegovy not just as a weight loss injection, but as a genuine, life-saving cardiovascular medicine. This is a significant moment — not just for patients and the NHS, but for the growing number of people accessing Wegovy safely through a regulated online pharmacy like Happy Pharmacy.

What Has NICE Actually Said?

In April 2026, NICE published final draft guidance recommending that semaglutide 2.4mg (Wegovy) should be made available on the NHS in England as a treatment option for adults with established cardiovascular disease — specifically those who have previously experienced a heart attack, stroke, or symptomatic peripheral arterial disease (PAD) — and who have a BMI of 27 or above. Crucially, this includes people who are simply overweight, not just those classified as obese. Around 1.2 million people in England are thought to be eligible, with NHS trusts expected to make the treatment available within 90 days of the guidance being finalised.

The treatment will be used alongside standard cardiovascular care — including statins and antihypertensives — and must be accompanied by a reduced-calorie diet and increased physical activity. In other words, Wegovy's role has expanded considerably. It is no longer just a support tool for weight loss. It is now a recognised intervention in the secondary prevention of life-threatening cardiovascular events.

The Science Behind the Shift: The SELECT Trial

This landmark guidance is underpinned by findings from the SELECT trial — a multinational, randomised, double-blind, placebo-controlled Phase 3 study involving 17,604 adults with established cardiovascular disease and a BMI of at least 27, but without diabetes.

The trial found that semaglutide reduced the risk of a first major adverse cardiovascular event — defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke — by 20% compared to placebo. Serious cardiovascular events occurred in 6.5% of participants receiving semaglutide, versus 8.0% in the placebo group — a meaningful 1.5 percentage point absolute risk reduction over the course of the trial.

SELECT Trial: Cardiovascular Event Rates

Serious cardiovascular events over the trial period (17,604 participants)

20% relative risk reduction in major cardiovascular events | Source: SELECT Trial, NEJM 2023

Critically, NICE noted that cardiovascular benefits were observed early in the trial — before significant weight loss had occurred. This strongly suggests that semaglutide's protective effect on the heart operates through mechanisms beyond weight reduction alone.  These may include improvements in blood pressure, inflammation, and arterial function — all risk factors for heart disease.

Who Is Eligible? Understanding the New Criteria

The new NICE guidance expands the eligibility criteria for Wegovy significantly. To qualify under this cardiovascular indication, a patient must meet all of the following:

•       Have a BMI of 27 kg/m² or above (overweight or obese)

•       Have established cardiovascular disease — meaning a previous heart attack, stroke, or symptomatic peripheral arterial disease

•       Be willing to follow a reduced-calorie diet and increase physical activity

•       Currently be receiving, or be suitable to receive, standard cardiovascular medicines such as statins

This is different from Wegovy's existing NICE-approved indication for weight management, which generally requires a higher BMI alongside weight-related health conditions. The cardiovascular guidance lowers the BMI threshold and focuses on a specific patient group with the highest personal risk.

Wegovy Eligibility at a Glance

What Does This Mean for Private Patients?

While NHS access to Wegovy for cardiovascular patients is set to expand significantly over the coming months, the reality is that NHS waiting lists for weight management services can still be lengthy — and not every patient will be offered Wegovy through a GP at the outset. This is where a GPhC-registered, regulated online pharmacy such as Happy Pharmacy provides an important alternative pathway for suitable patients.

At Happy Pharmacy, we believe that access to safe, clinically supervised weight loss injections should not be dictated by postcode or waiting time. Through our personal, medically supervised online consultation process, our prescribers can assess your full health profile — including cardiovascular history — to determine the most appropriate treatment pathway for you. Every prescription is issued by a registered UK prescriber, and every medication is sourced through licensed supply chains.

What About Mounjaro?

Mounjaro (tirzepatide) — which acts on both GLP-1 and GIP receptors — remains the leading weight loss injection in the UK private market, with four in five private patients currently using it for weight management.  While Mounjaro does not currently hold the same cardiovascular indication under NICE guidance as Wegovy, ongoing clinical trials are investigating its cardiovascular benefits, with results anticipated in the coming years.

For patients whose primary motivation is weight loss — without a specific history of cardiovascular events — Mounjaro may still be the most clinically appropriate option, delivering an average of approximately 20% body weight reduction at the highest dose. Your Happy Pharmacy prescriber will always assess which treatment is right for your individual health profile, goals, and medical history.

The important message is this: whether you are seeking support for weight loss, cardiovascular risk management, or both, there is now more clinical evidence than ever before to support the use of these medications — and more reason than ever to access them through a properly regulated, trustworthy provider.

Safety: What You Need to Know

Both Wegovy and Mounjaro are prescription-only medications that must be prescribed by a qualified healthcare professional following a clinical assessment. They are not suitable for everyone. Contraindications include a personal or family history of medullary thyroid cancer, pancreatitis, and pregnancy.

The MHRA has also issued warnings about the very real risks posed by counterfeit weight loss injections circulating through unregulated online channels. In 2025 alone, the MHRA seized almost 20 million doses of illegally traded medicines — with the most dangerous contaminant identified in counterfeit GLP-1 products being insulin, which can cause life-threatening hypoglycaemia in people who do not have diabetes.

At Happy Pharmacy, we only dispense genuine, MHRA-licensed medications from approved supply chains. Our consultations are conducted by registered UK prescribers, and we provide ongoing support throughout your treatment. Never purchase weight loss injections from unregulated sources — the consequences can be fatal.

The Bigger Picture: A New Chapter for Semaglutide

The April 2026 NICE guidance marks a watershed moment in how the medical community — and society as a whole — understands weight loss injections. Semaglutide is no longer simply a tool for shifting the number on the scales. It is now formally recognised as a medicine that can reduce the risk of heart attacks, strokes, and cardiovascular death in people with established heart disease.

This is a profound shift — one that reflects years of rigorous clinical research, and one that will change the lives of more than a million people in England alone. It also reinforces the importance of accessing these treatments through safe, regulated, and personal channels, with proper clinical oversight at every step.

If you have a history of heart attack, stroke, or peripheral arterial disease, and a BMI of 27 or above, come and take our free online weight loss consultation  to asses whether Wegovy could be right for you. We are here to provide expert, personal guidance — with your safety and long-term health at the heart of everything we do.

Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Happy Pharmacy prescribers conduct full clinical assessments before issuing any prescription.

References